This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2002 Jun;11(4):335-40; discussion 341-2.

doi: 10.1002/pds.740.

Issues in the approval of, access to, and post-marketing follow-up of new drugs in Canada: a personal viewpoint

Nigel S B Rawson¹

Affiliations

Affiliation

¹ Division of Community Health, Faculty of Medicine, School of Pharmacy, Memorial University of Newfoundland, St. John's, Newfoundland, Canada. nigel_rawson@uhc.com

PMID: 12138603
DOI: 10.1002/pds.740

Review

Issues in the approval of, access to, and post-marketing follow-up of new drugs in Canada: a personal viewpoint

Nigel S B Rawson. Pharmacoepidemiol Drug Saf. 2002 Jun.

. 2002 Jun;11(4):335-40; discussion 341-2.

doi: 10.1002/pds.740.

Author

Nigel S B Rawson¹

Affiliation

¹ Division of Community Health, Faculty of Medicine, School of Pharmacy, Memorial University of Newfoundland, St. John's, Newfoundland, Canada. nigel_rawson@uhc.com

PMID: 12138603
DOI: 10.1002/pds.740

No abstract available

PubMed Disclaimer

Comment in

Letter to the ISPE commentary editor.
Rawson NS. Rawson NS. Pharmacoepidemiol Drug Saf. 2003 Jan-Feb;12(1):71-2. doi: 10.1002/pds.799. Pharmacoepidemiol Drug Saf. 2003. PMID: 12616851 No abstract available.

Similar articles

Canadian and US drug approval times and safety considerations.
Rawson NS, Kaitin KI. Rawson NS, et al. Ann Pharmacother. 2003 Oct;37(10):1403-8. doi: 10.1345/aph.1D110. Ann Pharmacother. 2003. PMID: 14519031
Health Canada proposes new regulatory regime for drugs.
Kondro W. Kondro W. CMAJ. 2007 Apr 24;176(9):1261-2. doi: 10.1503/cmaj.070449. CMAJ. 2007. PMID: 17452653 Free PMC article. No abstract available.
Post-marketing strategies for medicines.
Breckenridge A. Breckenridge A. Clin Pharmacol Ther. 2008 Jan;83(1):24-5; discussion 25. doi: 10.1038/sj.clpt.6100427. Epub 2007 Nov 28. Clin Pharmacol Ther. 2008. PMID: 18043682 No abstract available.
Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval.
Borer JS, Pouleur H, Abadie E, Follath F, Wittes J, Pfeffer MA, Pitt B, Zannad F. Borer JS, et al. Eur Heart J. 2007 Aug;28(15):1904-9. doi: 10.1093/eurheartj/ehm209. Epub 2007 Jul 5. Eur Heart J. 2007. PMID: 17615083 Review.
Post-marketing experience with an opioid nasal spray for migraine: lessons for the future.
Loder E. Loder E. Cephalalgia. 2006 Feb;26(2):89-97. doi: 10.1111/j.1468-2982.2005.00951.x. Cephalalgia. 2006. PMID: 16426261 Review.

See all similar articles

Cited by

Lessons for a national pharmaceuticals strategy in Canada from Australia and New Zealand.
LeLorier J, Rawson NS. LeLorier J, et al. Can J Cardiol. 2007 Jul;23(9):711-8. doi: 10.1016/s0828-282x(07)70815-2. Can J Cardiol. 2007. PMID: 17622393 Free PMC article.
"Cost-effectiveness" estimates result in flawed decision-making in listing drugs for reimbursement.
West R, Borden EK, Collet JP, Rawson NS, Tonks RS. West R, et al. Can J Public Health. 2002 Nov-Dec;93(6):421-5. doi: 10.1007/BF03405029. Can J Public Health. 2002. PMID: 12448863 Free PMC article.
The Influence of Socioeconomic Status on Selection of Anticoagulation for Atrial Fibrillation.
Sholzberg M, Gomes T, Juurlink DN, Yao Z, Mamdani MM, Laupacis A. Sholzberg M, et al. PLoS One. 2016 Feb 25;11(2):e0149142. doi: 10.1371/journal.pone.0149142. eCollection 2016. PLoS One. 2016. PMID: 26914450 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Wiley